Please use this identifier to cite or link to this item:
Title: Sertraline in symptomatic chronic breathlessness: a double blind, randomised trial.
Austin Authors: Currow, David C;Ekström, Magnus;Louw, Sandra;Hill, Julie;Fazekas, Belinda;Clark, Katherine;Davidson, Patricia M;McDonald, Christine F ;Sajkov, Dimitar;McCaffrey, Nikki;Doogue, Matthew;Abernethy, Amy P;Agar, Meera
Affiliation: Deakin Health Economics, School of Health and Social Development, Deakin University, Burwood, Australia
Department of Medicine, Duke University, Carey, NC, USA
University of Otago, Christchurch and Canterbury District Health Board, Christchurch, New Zealand
School of Nursing, Johns Hopkins University, Baltimore, MD, USA
IMPACCT, Faculty of Health, University of Technology Sydney, Ultimo, Australia
Flinders Medical Centre, Dept of Respiratory and Sleep Medicine, Medical Centre Drive, Bedford Park, Australia
Respiratory and Sleep Medicine
Discipline of Palliative and Supportive Services, Flinders University, Adelaide, Australia
Dept of Clinical Sciences, Division of Respiratory Medicine and Allergology, Lund University, Lund, Sweden..
University of Sydney, Northern Clinical School, Royal North Shore Hospital, St Leonard's, Australia
McCloud Consulting Group, Narabang Way, Belrose, Australia
Issue Date: 17-Jan-2019 2019-01-17
Publication information: The European Respiratory Journal 2019; 53(1): 1801270
Abstract: Does sertraline provide symptomatic relief for chronic breathlessness in people with advanced disease whose underlying cause(s) are optimally treated?223 participants with chronic breathlessness (modified Medical Research Council breathlessness scale ≥2) who had optimal treatment of underlying cause(s) were randomised 1:1 to sertraline 25-100 mg (titrated upwards over 9 days) or placebo for 4 weeks. The primary outcome was the proportion who had an improvement in intensity of current breathlessness >15% from baseline on a 100-mm visual analogue scale.The proportion of people responding to sertraline was similar to placebo for current breathlessness on days 26-28 (OR 1.00, 95% CI 0.71-1.40) and for other measures of breathlessness. Quality of life in the sertraline arm had a higher likelihood of improving than in the placebo arm over the 4 weeks (OR 0.21, 95% CI 0.01-0.41; p=0.044). No differences in performance status, anxiety and depression, or survival were observed. Adverse event rates were similar between arms.Sertraline does not appear to provide any benefit over placebo in the symptomatic relief of chronic breathlessness in this patient population.
DOI: 10.1183/13993003.01270-2018
PubMed URL: 30361250
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Dec 2, 2022

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.